Form 4: Venrock Healthcare Capital Partners III, L.P. Increases Stake in KalVista Pharmaceuticals, Inc.

Venrock Healthcare Capital Partners III, L.P. reports purchasing 25,000 shares of KalVista Pharmaceuticals, Inc. common stock at a weighted average price of $9.42 on April 9, 2025, increasing their total holdings.

Summary

• On April 9, 2025, Venrock Healthcare Capital Partners III, L.P. acquired 25,000 shares of KalVista Pharmaceuticals, Inc. common stock.
• The shares were purchased at a weighted average price of $9.42, with individual prices ranging from $9.27 to $9.50.
• Following the transaction, Venrock Healthcare Capital Partners III, L.P. and related entities beneficially own a total of 5,303,985 shares.
• The reported beneficial ownership includes shares held by Venrock Healthcare Capital Partners III, L.P. (1,142,719 shares), VHCP Co-Investment Holdings III, LLC (114,312 shares), and Venrock Healthcare Capital Partners EG, L.P. (4,046,954 shares).
• VHCP Management III, LLC is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities.
• VHCP Management EG, LLC is the general partner of VHCPEG and may be deemed to beneficially own these securities.
• Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction disclosure, indicating continued investment but not necessarily a strong positive or negative signal.

Positives

• Increased investment by Venrock Healthcare Capital Partners III, L.P. may signal confidence in KalVista Pharmaceuticals, Inc.'s future prospects.

Industry Context

This filing reflects ongoing investment activity in the pharmaceutical sector, where investment firms like Venrock Healthcare Capital Partners frequently adjust their holdings based on company performance and market conditions.

Stakeholder Impact

• The increased stake by Venrock Healthcare Capital Partners III, L.P. could be viewed positively by shareholders.

Key Dates

Keywords

KalVista Pharmaceuticals, Venrock Healthcare Capital Partners, Beneficial Ownership, Share Purchase, Form 4, KALV, Investment